PCSK9 and familial hyperaldosteronism: A budget impact study was conducted, using a 3-year model of introducing PCSK9 inhibitors to treat adults with heterozygous FH or established ASCVD requiring additional LDL-C lowering for a hypothetical US health plan with one million members [77].